The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform
Dilara Turgut - One of the best experts on this subject based on the ideXlab platform.
-
Topical 0.05% Clobetasol Propionate versus 1% pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
-
topical 0 05 Clobetasol Propionate versus 1 pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
Steven R Feldman - One of the best experts on this subject based on the ideXlab platform.
-
topical Clobetasol Propionate in the treatment of psoriasis a review of newer formulations
American Journal of Clinical Dermatology, 2009Co-Authors: Steven R Feldman, Brad A YentzerAbstract:Ultrapotent topical corticosteroids are the mainstay of psoriasis treatment, used either alone or in combination with a topical vitamin D analog. Traditionally used in an ointment vehicle for psoriasis, Clobetasol Propionate 0.05% is also available in spray, foam, lotion, and shampoo formulations, which may provide for improved convenience and acceptance in many patients with similar efficacy, safety, and tolerability as the traditional ointment and cream formulations. To compare newer formulations with traditional ointment and cream formulations, we performed a systematic review of the literature. Search terms included ‘Clobetasol Propionate,’ in combination with ‘psoriasis,’ ‘vasoconstriction,’ ‘vasoconstrictor,’ or ‘absorption’ for each of the four vehicles (‘spray,’ ‘foam,’ ‘lotion,’ and ‘shampoo’).
-
Clobetasol Propionate for psoriasis are ointments really more potent
Journal of Drugs in Dermatology, 2006Co-Authors: Lindsey Warino, Rajesh Balkrishnan, Steven R FeldmanAbstract:BACKGROUND: Clobetasol Propionate is the most common topical therapy used for psoriasis in the US. Conventional dermatologic wisdom is that ointment preparations provide the highest potency (due to their occlusive nature and moisturizing ability) and are best suited for psoriasis. However, patients often find application of ointment to be messy, raising concerns about both short-term and long-term adherence to treatment. This article reviews the current literature and assesses the relative potency of Clobetasol Propionate ointment compared to other Clobetasol Propionate preparations in the treatment of psoriasis. Relevant literature was identified by PubMed and Google searches. We included studies of psoriasis that reported the percentage of subjects that achieved desired efficacy endpoints, as well as studies that reported the subjects' mean change in symptoms from baseline. We excluded studies conducted before 1980 and those that allowed concomitant treatments. OBSERVATIONS: Efficacy rates ranged from 17% to 80% for the different vehicles: ointment, solution, foam, cream, lotion, shampoo, and emollient. CONCLUSIONS: Clobetasol Propionate is a very effective treatment for psoriasis. Ointment preparations have similar efficacy to other preparations in clinical trial situations. In clinical practice, a situation in which patient preferences are more likely to affect compliance, it may be best to choose whichever vehicle patients find preferable.
-
Clobetasol Propionate lotion an efficient and safe alternative to Clobetasol Propionate emollient cream in subjects with moderate to severe plaque type psoriasis
Journal of Dermatological Treatment, 2005Co-Authors: Nicholas J. Lowe, Daniel W Sherer, Joel S Shavin, Valerie Foley, Jonathan Weiss, Steven R Feldman, Pascale SotoAbstract:Background: Various formulations of Clobetasol Propionate are currently used to treat psoriasis due to its anti‐inflammatory, anti‐pruritic, vasoconstrictive and immunomodulating properties. Objective: To assess the efficacy, safety and remission profile of Clobetasol Propionate lotion compared to that of Clobetasol Propionate emollient cream and lotion vehicle in subjects with moderate to severe plaque‐type psoriasis. Methods: Multicentre, investigator‐blind, randomized, active‐ and vehicle‐controlled, parallel‐group study. Results: A total of 192 subjects were treated: 82 with Clobetasol Propionate lotion, 81 with Clobetasol Propionate cream and 29 with the vehicle. Clobetasol Propionate lotion was significantly more effective than vehicle lotion and was comparable in efficacy to the emollient cream after 4 weeks of treatment. Treatment success was higher for subjects in the Clobetasol Propionate lotion group than in the emollient cream group after 4 weeks of a treatment‐free follow‐up period. Clobetaso...
-
The use of 0.25% zinc pyrithione spray does not enhance the efficacy of Clobetasol Propionate 0.05% foam in the treatment of psoriasis.
Journal of The American Academy of Dermatology, 2003Co-Authors: Tamara Salam Housman, Alan B Fleischer, Kimberly A. Keil, Beverly G. Mellen, Martha Ann Mccarty, Steven R FeldmanAbstract:Abstract Background: It was discovered that Skin Cap (Cheminova Internacional S.A., Madrid, Spain), an over-the-counter psoriasis therapy with zinc pyrithione, contained Clobetasol Propionate and it was withdrawn from the market by the US Food and Drug Administration review. Some suggested that there might be a synergistic effect of zinc pyrithione with Clobetasol Propionate. Objective: We sought to evaluate the efficacy of Clobetasol Propionate 0.05% foam with and without the coadministration of a topical 0.25% zinc pyrithione spray in treating psoriasis involving sites other than the scalp. Methods: We conducted a randomized, double-blind, right/left study of patients with mild to moderate, generally symmetric, plaque-type psoriasis. Patients were assigned to treatment with Clobetasol Propionate foam on all psoriatic lesions and then randomly assigned to use zinc pyrithione spray to either the right or left side of their body (vehicle spray to be applied to the opposite side). There was a 2-week treatment phase (visits at baseline, week 1, and week 2) and a follow-up phase (visit at week 4), and all treatments were administered twice daily for 2 weeks. The primary outcome measure was the change from baseline to week 2 in the composite score of the signs of psoriasis (erythema, scaling, plaque thickness) for symmetric target lesions. Results: A total of 25 patients were enrolled; 24 completed the trial and 1 was lost to follow up. Of those who completed the study, 63% (15 of 24) were men, and the mean age (±SD) was 50 years (±12.2). After 2 weeks of therapy, the average decline in the composite score was 3.5 (±1.8) for monotherapy (Clobetasol Propionate foam and vehicle) and, similarly, 3.3 (±1.8) for Clobetasol Propionate foam plus zinc pyrithione spray ( P = .5). Discussion: Zinc pyrithione spray does not appear to enhance the efficacy of Clobetasol Propionate foam after 2 weeks of therapy. (J Am Acad Dermatol 2003;49:79-82.)
-
bioavailability of Clobetasol Propionate in different vehicles
Skin Pharmacology and Physiology, 2003Co-Authors: T. J. Franz, P A Lehman, Steven R Feldman, M C SpellmanAbstract:Topical Clobetasol Propionate is widely used for the treatment of psoriasis. One formulation of Clobetasol Propionate, Skin Cap, was thought by some practitioners and patients to be more effective tha
Basak Kandi Coskun - One of the best experts on this subject based on the ideXlab platform.
-
Topical 0.05% Clobetasol Propionate versus 1% pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
-
topical 0 05 Clobetasol Propionate versus 1 pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
Yunus Saral - One of the best experts on this subject based on the ideXlab platform.
-
Topical 0.05% Clobetasol Propionate versus 1% pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
-
topical 0 05 Clobetasol Propionate versus 1 pimecrolimus ointment in vitiligo
European Journal of Dermatology, 2005Co-Authors: Basak Kandi Coskun, Yunus Saral, Dilara TurgutAbstract:Vitiligo is a common skin condition resulting from loss of normal melanin pigments in the skin which produces white patches. Topical corticosteroids are indicated for the treatment of limited areas of vitiligo. Pimecrolimus, which inhibits calcineurin, has recently been shown to be effective for the treatment of vitiligo. We performed a prospective study to evaluate the efficacy of the 0.05% Clobetasol Propionate and 1% pimecrolimus in the treatment of vitiligo. Ten patients with virtually bilateral symmetrical lesions of vitiligo were included. 0.05% Clobetasol Propionate was applied twice daily over the lesion on right side of the body, and topical 1% pimecrolimus was applied twice daily over the lesion on left side of the body. It was determined that both treatment modalities resulted in a comparable rate of repigmentation. Response to treatment was varied according to the anatomical location of the lesions where better results were seen on the trunk and extremities. Results from this pilot study indicate that topical 1% pimecrolimus is as effective as Clobetasol Propionate in restoring skin disfiguring due to vitiligo. For a better conclusive statement further studies involving larger groups of patients should be performed.
Colombina Vincenzi - One of the best experts on this subject based on the ideXlab platform.
-
Clobetasol Propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis.
Journal of The American Academy of Dermatology, 2003Co-Authors: Antonella Tosti, Bianca Maria Piraccini, Massimiliano Pazzaglia, Colombina VincenziAbstract:Abstract Background: Efficacy of topical steroids in alopecia areata is still discussed. Objective: The purpose of this study was to evaluate the efficacy of Clobetasol Propionate 0.05% ointment under occlusion in 28 patients with alopecia areata totalis (AT) or AT/alopecia universalis. Methods: A total of 28 patients were instructed to apply 2.5 g of Clobetasol Propionate to the right side of the scalp every night under occlusion with a plastic film. Treatment was performed 6 days a week for 6 months. When regrowth of terminal hair occurred, treatment was extended over the entire scalp. All patients were followed up for another 6 months. Results: Of the 28 patients included in the study, 8 were treated successfully (28.5%). Regrowth of terminal hair began on the treated side 6 to 14 weeks after the start of treatment. Of these 8 patients, 3 had a relapse and were not able to maintain hair regrowth. Conclusion: Our study shows that Clobetasol Propionate 0.05% under occlusion is effective in inducing hair regrowth in patients with AT or AT/alopecia universalis. Occurrence of hair regrowth only on the treated half of the scalp clearly shows that efficacy of treatment is a result of a local and not systemic effect of the drug. Although only 17.8% of patients had long-term benefit by treatment, our results were obtained in a population of patients with severe and refractory forms of the disease. (J Am Acad Dermatol 2003;49:96-8.)
-
Clobetasol Propionate 0 05 under occlusion in the treatment of alopecia totalis universalis
Journal of The American Academy of Dermatology, 2003Co-Authors: Antonella Tosti, Bianca Maria Piraccini, Massimiliano Pazzaglia, Colombina VincenziAbstract:Abstract Background: Efficacy of topical steroids in alopecia areata is still discussed. Objective: The purpose of this study was to evaluate the efficacy of Clobetasol Propionate 0.05% ointment under occlusion in 28 patients with alopecia areata totalis (AT) or AT/alopecia universalis. Methods: A total of 28 patients were instructed to apply 2.5 g of Clobetasol Propionate to the right side of the scalp every night under occlusion with a plastic film. Treatment was performed 6 days a week for 6 months. When regrowth of terminal hair occurred, treatment was extended over the entire scalp. All patients were followed up for another 6 months. Results: Of the 28 patients included in the study, 8 were treated successfully (28.5%). Regrowth of terminal hair began on the treated side 6 to 14 weeks after the start of treatment. Of these 8 patients, 3 had a relapse and were not able to maintain hair regrowth. Conclusion: Our study shows that Clobetasol Propionate 0.05% under occlusion is effective in inducing hair regrowth in patients with AT or AT/alopecia universalis. Occurrence of hair regrowth only on the treated half of the scalp clearly shows that efficacy of treatment is a result of a local and not systemic effect of the drug. Although only 17.8% of patients had long-term benefit by treatment, our results were obtained in a population of patients with severe and refractory forms of the disease. (J Am Acad Dermatol 2003;49:96-8.)